EmpowerPharm, independent research report by Crystal Research Associates
EmpowerPharm Inc. (“EmpowerPharm” or “the Company”) is a Canadian pharmaceutical company dedicated to developing pharmaceutical grade cannabidiol (CBD)† therapies in solid oral dose formats. Its primary focus is on advancing treatments for mental health disorders, particularly social anxiety disorder (SAD). The Company applies its proprietary formulations based on SelfNanoemulsifying Drug Delivery System (SNEDDS) technology to […]
Revolutionizing Adult Epilepsy Treatment: Our Expanded Research Using Super SNEDDS Technology
In the evolving landscape of neurological disorders, epilepsy stands out as a complex challenge that affects millions of adults worldwide. The quest for more effective treatments has led us to innovate and explore groundbreaking methodologies in drug delivery systems. At the forefront of our research is the expanded application of our advanced Super Self-Nanoemulsifying Drug Delivery System (Super SNEDDS) technology.
EmpowerPharm Inc. is delighted to announce the outcome of their Phase 2 clinical trial assessing Cannabidiol (CBD) drug product for Social Anxiety Disorder (SAD)
EmpowerPharm Inc. https://empowerpharm.ca/ is delighted to announce the outcome of their Phase 2 clinical trial assessing the dose finding, efficacy, safety, and tolerability of Cannabidiol (CBD) drug product for Social Anxiety Disorder (SAD). The results demonstrated efficacy for a subset of patients suffering from moderate to severe SAD.
EMPOWERPHARM AWAITS PHASE II CLINICAL TRIAL ON GROUND BREAKING TREATMENT TO MANAGE SOCIAL ANXIETY DISORDER
Burlington, ON March 11, 2024 – EmpowerPharm Inc. is delighted to announce that the final participant has completed their treatment in the Phase II clinical trial assessing the efficacy of pharmaceutical-grade Cannabidiol (CBD) for Social Anxiety Disorder. The anticipated release of the top-line results are due next month in April.
EmpowerPharm Patent- PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF CANNABINOIDS was published today.
EmpowerPharm® a clinical stage pharmaceutical company specializing in cannabinoid-based drug development of prescription products. These products target therapeutic indications where patients need safe and efficacious treatment alternatives to currently available medical options. In addition, EmpowerPharm specializes in the development of novel, solid oral dose formulations for challenging drug molecules demonstrating low aqueous solubility, low bioavailability […]
EmpowerPharm Inc. is pleased to report that the final patient has successfully completed treatment and played an active role in the Phase II clinical trial on evaluating the potential of Cannabidiol in managing Social Anxiety Disorder.
EmpowerPharm Inc., a clinical-stage pharmaceutical company dedicated to research and clinical advancement, disclosed today that the last participant concluded the treatment and active involvement
EmpowerPharm and Stella’s Place host Mental Health Forum
This was a virtual panel discussion between leading clinical experts on the state of anxiety in Canada discussing existing and emerging treatments and trends. The panelist were as follows: • Dr. Jitender Sareen, Head of the Department of Psychiatry, University of Manitoba• Dr. Peggy Richter, Head of the Frederick W. Thompson Anxiety Disorders Centre, Sunnybrook […]
EmpowerPharm Inc featured on Advancements with Ted Danson series
EmpowerPharm Inc was pleased to be invited to participate as a featured guest on the Advancements with Ted Danson series, broadcasted throughout North America.
EmpowerPharm Inc. Announces First Patient Dosed in a Phase II Study Evaluating Empower CBD™ for the Treatment of Social Anxiety Disorder
EmpowerPharm Inc a clinical-stage life sciences company focused on research and clinical development announced today that the first patient has been dosed in their Company-sponsored Phase II clinical study.
EmpowerPharm Inc. Announces First Patient Enrolled in a Phase II Study Evaluating Empower CBD™ for the Treatment of Social Anxiety Disorder
EmpowerPharm Inc a clinical-stage life sciences company focused on research and clinical development announced today that the first patient has been enrolled in their Company-sponsored Phase II clinical study.